08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
Three recent antitrust merger reviews involving nascent competition demonstrate enforcers are paying...
Read More >
Seyfarth Synopsis: In our fourth installment on the presidential candidates’ stances on future of w...
Read More >
Over the past year, the popularity of digital workplace apps (that is, mobile applications used by c...
Read More >
On Tuesday, February 11, 2020, the Equal Employment Opportunity Commission filed a complaint against...
Read More >
The Pennsylvania Supreme Court upheld the Pittsburgh Paid Sick Days Act (“PSDA”) in a decision tod...
Read More >
For many years, the development industry in Florida has been able to extend building permits, develo...
Read More >